DIAGNOSTIC TECHNIQUE FOR VAGINITIS IN PREGNANT WOMEN BY INTERLEUKINE GENE IRNA EXPRESSION IN VAGINAL SMEARS Russian patent published in 2014 - IPC C12Q1/68 G01N33/50 

FIELD: medicine.

SUBSTANCE: invention refers biotechnology and medicine. What is presented is a method based on measuring interleukin IL1B, IL8, IL10 and IL18 gene iRNA expression in vaginal smears in relation to the presence of iRNA of the reference genes B2M, GUS, TBP or HPRT; the derived expressions are used to calculate canonical linear discriminant function (CLDF) as follows: Y=1.09*IL1B-0.61*IL8+0.21*IL10-0.11*IL18-0.91 (formula 1), wherein IL1B is relative IL1B expression, IL8 is relative IL8 expression, IL10 is relative IL10 expression, IL18 is relative IL18 expression; IL=2^(Cpmin-Cpil)/NF (formula) wherein IL is relative interleukin gene expression, Cpmin is a coefficient of minimum expression, for IL1B Cpmin=17.9; IL8 Cpmin=16.6; IL10 Cpmin=28.8; IL18 Cpmin=23.3; Cpil is a threshold cycle of related IL in a sample determined automatically; NF is a rate setting factor calculated by formula 3: $$\text{NF}{=}^{\text{4}}\sqrt{\text{NFgus*NFhprt*NFb2m*NFtbp}}$$ (formula 3) wherein NF is a rate setting factor calculated as a geometrical mean of 4 rate setting factors for reference genes (see formula 4); NFref=2^(Cpmin-Cpref) (formula 4), wherein NFref is a rate setting factor for the reference gene, Cpmin is a coefficient for minimum expression of the reference gene, Cpref is the threshold readings in the sample; Cpmin for the reference genes are as follows: GUS Cpmin=26.5; HPRT Cpmin=26.8; B2M Cpmin=18.9; TBP Cpmin=28.4; if CLDF≤0.1, the absence of vaginitis is stated; CLDF>0.1 stands for vaginistis.

EFFECT: invention enables the objective detection of the presence of vaginitis in a pregnant woman.

2 cl, 1 dwg, 3 tbl, 3 ex